Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Review

Hsp90 regulates autophagy and plays a role in cancer therapy

Authors: Benli Wang, Zongyan Chen, Feifei Yu, Qiao Chen, Yuxi Tian, Shumei Ma, Tiejun Wang, Xiaodong Liu

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Nowadays, heat shock protein 90 (Hsp90), a highly conserved molecular chaperone, has become the target of antitumor drugs as a result of its close relationship with the occurrence and development, biological behavior, and prognosis of a tumor. Autophagy has attracted big attention recently for its paradoxical roles in cell survival and cell death, especially in the pathogenesis and treatment of cancer. Moreover, it has been verified that Hsp90 plays a role in autophagy via regulating the stability and activity of signaling proteins, and some Hsp90 inhibitors can induce autophagy. However, the underlying mechanisms for these important processes have not been clarified so far. In this study, we focus on the roles of Hsp90 in the regulation of autophagy, such as toll-like receptor (TLR)-mediated autophagy, Ulk1-mediated mitophagy, and chaperone-mediated autophagy (CMA). The roles of Hsp90 inhibitors in cancer therapy will also be elucidated.
Literature
1.
Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475:324–32.CrossRefPubMed
2.
Taipale M, Jarosz DF, Lindquist S. Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Bio. 2010;11:515–28.CrossRef
3.
Fearns C, Pan Q, Mathison JC, Chuang TH. Triad3a regulates ubiquitination and proteasomal degradation of rip1 following disruption of HSP90 binding. J Biol Chem. 2006;281:34592–600.CrossRefPubMed
4.
Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of HSP90. J Mol Med-Jmm. 2004;82:488–99.
5.
Haupt A, Joberty G, Bantscheff M, Frohlich H, Stehr H, Schweiger MR, et al. Hsp90 inhibition differentially destabilises map kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer. 2012;12:38.CrossRefPubMedPubMedCentral
6.
Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treatment Reviews. 2013;39:375–87.CrossRefPubMed
7.
Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci. 2007;1113:202–16.CrossRefPubMed
8.
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51–64.CrossRefPubMedPubMedCentral
9.
Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.CrossRefPubMed
10.
Wang B, Chen L, Ni Z, Dai X, Qin L, Wu Y, et al. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (−)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells. Exp Cell Res. 2014;328:379–87.CrossRefPubMed
11.
Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy. 2007;3:635–7.CrossRefPubMed
12.
13.
Randhawa R, Sehgal M, Singh TR, Duseja A, Changotra H. Unc-51 like kinase 1 (ULK1) in silico analysis for biomarker identification: a vital component of autophagy. Gene. 2015;562:40–9.CrossRefPubMed
14.
Rout AK, Strub MP, Piszczek G, Tjandra N. Structure of transmembrane domain of lysosomal-associated membrane protein type 2a (LAMP-2A) reveals key features for substrate specificity in chaperone mediated autophagy. J Biol Chem. 2014;289(51):35111–23.CrossRefPubMedPubMedCentral
15.
Babik W, Dudek K, Fijarczyk A, Pabijan M, Stuglik M, Szkotak R, et al. Constraint and adaptation in newt toll-like receptor genes. Genome Biol Evol. 2014;7(1):81–95.CrossRefPubMedPubMedCentral
16.
Skabytska Y, Wolbing F, Gunther C, Koberle M, Kaesler S, Chen KM, et al. Cutaneous innate immune sensing of toll-like receptor 2–6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity. 2014;41:762–75.CrossRefPubMed
17.
Lee MS, Min YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem. 2007;76:447–80.CrossRefPubMed
18.
Sasai M, Yamamoto M. Pathogen recognition receptors: ligands and signaling pathways by toll-like receptors. International reviews of immunology. 2013;32:116–33.CrossRefPubMed
19.
Huang J, Brumell JH. Autophagy in immunity against intracellular bacteria. Curr Top Microbiol. 2009;335:189–215.
20.
Muenz C. Enhancing immunity through autophagy. Annu Rev Immunol. 2009;27:423–49.CrossRef
21.
Xu Y, Liu XD, Gong X, Eissa NT. Signaling pathway of autophagy associated with innate immunity. Autophagy. 2008;4:110–2.CrossRefPubMed
22.
23.
Xu C, Liu J, Hsu LC, Luo Y, Xiang R, Chuang TH. Functional interaction of heat shock protein 90 and Beclin 1 modulates toll-like receptor-mediated autophagy. FASEB J. 2011;25:2700–10.CrossRefPubMedPubMedCentral
24.
Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, et al. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Autophagy. 2015;11:113–30.CrossRefPubMedPubMedCentral
25.
Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10:524–30.CrossRefPubMed
26.
de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010;51:391–405.PubMed
27.
Bhatia-Kissova I, Camougrand N. Mitophagy in yeast: actors and physiological roles. FEMS Yeast Res. 2010;10:1023–34.CrossRefPubMed
28.
Hirota Y, Aoki Y, Kanki T. Mitophagy: selective degradation of mitochondria by autophagy. Seikagaku. 2011;83:126–30.PubMed
29.
Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, et al. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Molecular cell. 2011;43:572–85.CrossRefPubMedPubMedCentral
30.
31.
Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, Piper PW, et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell. 2004;116:87–98.CrossRefPubMed
32.
Dorsey FC, Rose KL, Coenen S, Prater SM, Cavett V, Cleveland JL, et al. Mapping the phosphorylation sites of Ulk1. J Proteome Res. 2009;8:5253–63.CrossRefPubMed
33.
Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010;12:119–U170.CrossRefPubMed
34.
Weihofen A, Ostaszewski B, Minami Y, Selkoe DJ. Pink1 parkinson mutations, the Cdc37/Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1. Hum Mol Genet. 2008;17:602–16.CrossRefPubMed
35.
Chan EYW, Longatti A, McKnight NC, Tooze SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. Mol Cell Biol. 2009;29:157–71.CrossRefPubMed
36.
Kundu M, Lindsten T, Yang CY, Wu J, Zhao F, Zhang J, et al. Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturation. Blood. 2008;112:1493–502.CrossRefPubMedPubMedCentral
37.
38.
Zhang L, Sun Y, Fei M, Tan C, Wu J, Zheng J, et al. Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization. Autophagy. 2014;10:1015–35.CrossRefPubMedPubMedCentral
39.
Massey AC, Zhang C, Cuervo AM. Chaperone-mediated autophagy in aging and disease. Curr Top Dev Biol. 2006;73:205–35.CrossRefPubMed
40.
Dohi E, Tanaka S, Seki T, Miyagi T, Hide I, Takahashi T, et al. Hypoxic stress activates chaperone-mediated autophagy and modulates neuronal cell survival. Neurochem Int. 2012;60:431–42.CrossRefPubMed
41.
Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13:137–45.CrossRefPubMed
42.
Eskelinen EL, Schmidt CK, Neu S, Willenborg M, Fuertes G, Salvador N, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1/LAMP-2 double-deficient fibroblasts. Mol Biol Cell. 2004;15:3132–45.CrossRefPubMedPubMedCentral
43.
Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. Embo J. 2007;26:313–24.CrossRefPubMedPubMedCentral
44.
Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996;273:501–3.CrossRefPubMed
45.
Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol. 2008;28:5747–63.CrossRefPubMedPubMedCentral
46.
Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res. 2006;95:323–48.CrossRefPubMed
47.
Franke J, Eichner S, Zeilinger C, Kirschning A. Targeting heat-shock-protein 90 (HSP90) by natural products: geldanamycin, a show case in cancer therapy. Nat Prod Rep. 2013;30:1299–323.CrossRefPubMed
48.
Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002;8:S55–61.CrossRefPubMed
49.
Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr-Relat Cancer. 2006;13:S125–35.CrossRefPubMed
50.
Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, et al. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015;46:47–54.PubMed
51.
Geng M, Wang L, Chen X, Cao R, Li P. The association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancer. Diagn Pathol. 2013;8:198.CrossRefPubMedPubMedCentral
52.
Hadley KE, Hendricks DT. Use of NQO1 status as a selective biomarker for oesophageal squamous cell carcinomas with greater sensitivity to 17-AAG. BMC Cancer. 2014;14:334.CrossRefPubMedPubMedCentral
53.
Dudas J, Schartinger VH, Romani A, Schweigl G, Kordsmeyer K, Marta PI, et al. Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer. Tumour Biol. 2014;35:7807–19.CrossRefPubMedPubMedCentral
54.
Zaanan A, Dalban C, Emile JF, Blons H, Flejou JF, Goumard C, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatin-based adjuvant chemotherapy. J Cancer. 2014;5:425–32.CrossRefPubMedPubMedCentral
55.
Zhang Z, Xie Z, Sun G, Yang P, Li J, Yang H, et al. Reversing drug resistance of cisplatin by HSP90 inhibitors in human ovarian cancer cells. Int J Clin Exp Med. 2015;8:6687–701.PubMedPubMedCentral
56.
57.
Sun Y, Xiao S, Chen J, Wang M, Zheng Z, Song S, et al. Heat shock protein 90 mediates the apoptosis and autophage in nicotinic-mycoepoxydiene-treated HeLa cells. Acta Biochim Biophys Sin (Shanghai). 2015;47:451–8.CrossRef
Metadata
Title
Hsp90 regulates autophagy and plays a role in cancer therapy
Authors
Benli Wang
Zongyan Chen
Feifei Yu
Qiao Chen
Yuxi Tian
Shumei Ma
Tiejun Wang
Xiaodong Liu
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4142-3

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound

Original Article

Contribution of resident and recruited macrophages to the photodynamic intervention of colorectal tumor microenvironment

Original Article

Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population

Review

The role of cullin proteins in gastric cancer

Original Article

CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p

Review

Cancer stem cells in human digestive tract malignancies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits